Adhera Therapeutics Stock News

CG Oncology (NASDAQ: CGON - Get Free Report) and Adhera Therapeutics (OTCMKTS:ATRX - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies

Adhera Therapeutics, Inc. (OTCMKTS:ATRX) was the recipient of a significant drop in short interest in November. As of November 15th, there was short interest totalling 2,100 shares, a drop of 32.3% from the October 31st total of 3,100 shares. Based on an average daily volume of 285,100 shares, the days-to-cover ratio is currently 0.0 days. []

Baton Rouge, LA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new Canadian patent has been issued for MLR-1019 (armesocarb), a drug licensed by the Company from Melior Discovery (Melior) company Melior Pharmaceuticals II, LLC (Melior 2). Melior has received a Notice of Allowance from the Canadian Intellectual Property Office for the patent, titled, Methods of Treating Dyskinesia and Related Disorders.

Adhera Therapeutics, Inc. (OTCMKTS:ATRX) was the target of a large increase in short interest during the month of October. As of October 29th, there was short interest totalling 3,100 shares, an increase of 342.9% from the October 14th total of 700 shares. Based on an average daily trading volume, of 252,300 shares, the short-interest ratio []

IP Estate Grows with New Korean Patent Issued

With a new year fast approaching, these biotech penny stocks may benefit from the shifting winds in the broader healthcare market. The post 7 Biotech Penny Stocks With Huge Catalysts Coming in 2022 ap

Baton Rouge, LA, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new Eu